From Zacks Investment Research: 2025-06-06 13:10:00

Shares of Kura Oncology (KURA) surged 15.5% as FDA accepted NDA for ziftomenib in NPM1-mutant AML. The NDA was supported by a phase II study showing promising remission rates and safety data. A $45M milestone from Kyowa Kirin was triggered upon NDA submission in Q2 2025. If approved, ziftomenib would be the first menin inhibitor for R/R NPM1-mutant AML. Kura Oncology’s lead product candidate, ziftomenib, is an oral menin inhibitor with strong potential. The FDA has granted ziftomenib multiple designations for AML treatment. Kura Oncology is also developing other pipeline products for solid tumors and head and neck cancer. Consider Kura Oncology stock due to upcoming FDA decision and clinical milestones.



Read more at Zacks Investment Research: KURA Stock Rises More Than 15% This Past Week: Here’s Why – June 6, 2025